Ecallantide
A kallikrein blocker for hereditary angioedema attacks
Ecallantide is a 60-amino-acid recombinant protein that blocks plasma kallikrein, the enzyme that releases bradykinin during hereditary angioedema attacks. Approved as Kalbitor in 2009, it is injected under the skin during an attack, but only by a healthcare professional because of a risk of anaphylaxis.
Manufacturer's recommended dosing (FDA label): 30 mg (3 mL) as three 10 mg (1 mL) injections; if the attack persists, another 30 mg may be given within 24 hours, Per attack, Subcutaneous Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
Work out syringe units → · New to syringes? · All dosing data ↓
What is it?
Hereditary angioedema causes recurrent attacks of swelling of the skin, gut and airway, driven by bradykinin. Ecallantide blocks plasma kallikrein, the enzyme that releases bradykinin, and so treats an attack once it has started. At 60 amino acids it is a small protein rather than a peptide by FDA's definition, which is why it was licensed as a biologic. It is approved for people aged 12 and older.
In the EDEMA4 trial of 72 patients with moderate to severe attacks, the median treatment outcome score at four hours was 50 on ecallantide against 0 on placebo, with no treatment-related serious adverse events. The EDEMA3 trial found a similar four-hour benefit.
Throat swelling is the attack that kills, and pooled data cover it. Across four studies, 98 patients received ecallantide for 220 laryngeal attacks; the median time to significant improvement was 185 minutes, and one attack needed intubation. Younger patients were pooled the same way: 25 patients aged 9 to 17, treated for 62 attacks, improved more at four hours than those on placebo and reached near-complete resolution in a median of 181 minutes.
Swelling caused by ACE inhibitors is also driven by bradykinin, so ecallantide was tried there. A small emergency department pilot found 31% on ecallantide against 21% on placebo ready for discharge within four hours, and a larger trial of 79 patients found no significant difference. It is not approved for that use.
Repeat use held up. In a continuation study, 147 patients were treated for 625 attacks with no sign of the drug losing effect, and in the phase 3 trials worsening after an initial response was uncommon and mostly judged relapse rather than rebound. Ecallantide was also tested to reduce bleeding in heart surgery on bypass; that trial was stopped early because more patients died on ecallantide than on tranexamic acid (12% against 4%).
Its limitation is anaphylaxis. Across 230 patients and 1,045 doses, 3.5% had reactions meeting criteria for anaphylaxis, none on first exposure and all within an hour. The label carries a boxed warning and requires administration by a healthcare professional able to manage anaphylaxis. Its half-life is about two hours.
Mechanism of Action
Ecallantide is a 60-amino-acid Kunitz-domain protein, engineered from tissue factor pathway inhibitor, that blocks plasma kallikrein and so cuts off the release of bradykinin.
Plasma kallikrein
Binds and inhibits plasma kallikrein, the enzyme that cleaves high-molecular-weight kininogen to release bradykinin.
Less bradykinin, less leakage
Bradykinin opens blood vessels and makes them leak; blocking its release treats the swelling of an attack.
Short-lived
After a 30 mg dose, levels peak at 2 to 3 hours and fall with a half-life of about 2 hours; it is cleared partly by the kidneys (label).
Published Research
The trials and safety data behind ecallantide, from their PubMed abstracts.
EDEMA4: phase 3
In 72 patients with acute attacks, the median treatment outcome score at 4 hours was 50.0 on ecallantide against 0.0 on placebo (P = 0.004), with symptom severity improving more; there were no deaths, treatment-related serious adverse events or withdrawals for adverse events.
Not for ACE-inhibitor angioedema
In 79 emergency patients with angioedema from ACE inhibitors, discharge criteria were met by 72% on placebo and 85% to 89% on ecallantide 10 to 60 mg, a difference that was not significant.
How often a second dose is needed
Across 732 hereditary angioedema attacks in 179 patients, one 30 mg dose sufficed for 88%; a second dose was needed most often for peripheral attacks (16.5%).
Laryngeal attacks
Pooled from four studies, 98 patients received ecallantide for 220 laryngeal attacks; median time to significant improvement was 185 minutes, one attack needed intubation, and there were 2 anaphylactic reactions, both followed by full recovery.
Patients under 18
In 25 patients aged 9 to 17 treated for 62 attacks, symptom severity fell more at four hours than on placebo (MSCS -1.4 against -0.9; TOS 73.9 against 45.0), median time to near-complete resolution was 181 minutes, and no treatment-related serious adverse events occurred.
ACE-inhibitor angioedema pilot
In a triple-blind emergency department pilot of ACE-inhibitor angioedema not helped by standard therapy, 31% on ecallantide against 21% on placebo met discharge criteria within four hours, a difference with a confidence interval spanning zero (-14% to 34%).
Repeated attacks: continuation study
In an open-label continuation study, 147 patients were treated for 625 attacks with no sign of reduced effect on repeat use; 8 patients (5.4%) had possible hypersensitivity reactions, 6 of which met criteria for anaphylaxis.
Rebound and relapse
Of 70 ecallantide-treated patients in the phase 3 trials, 42 improved enough by four hours to be assessed; among nine who worsened by 24 hours, one was possible rebound and three possible or likely relapse.
Cardiac surgery: stopped early
In 218 patients having high-bleeding-risk cardiac surgery, the trial was stopped early when 30-day mortality was 12% on ecallantide against 4% on tranexamic acid; ecallantide patients also needed more red cell transfusion (median 900 against 300 mL).
EDEMA3 and the evidence base
A review describing ecallantide as a selective, reversible plasma kallikrein inhibitor and summarising EDEMA3, in which a single 30 mg dose produced a significantly greater symptom response at 4 hours than placebo.
Anaphylaxis after ecallantide
Among 230 patients given 1,045 doses, 8 (3.5%) had reactions meeting anaphylaxis criteria, none on first exposure, all within 1 hour, and all resolved with standard treatment.
Role in managing attacks
A review of hereditary angioedema treatment placing ecallantide among on-demand therapies for acute attacks, alongside long-term and short-term prophylaxis.
Dosing Data
Kalbitor is given during an attack as 30 mg under the skin, split into three 10 mg injections, by a healthcare professional with support to manage anaphylaxis.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Kalbitor (ecallantide injection): KALBITOR is a clear, colorless liquid free of preservatives. Each vial of KALBITOR contains ecallantide at a concentration of 10 mg/mL. Single-dose glass vial containing 10 mg/mL of ecallantide as a solution for injection. Forms the label lists: vials.
Source: Kalbitor (ecallantide injection) label, section 3 (DailyMed version 19, effective July 1, 2025).
Mixing a vial: a worked example
Nothing to mix: the label gives Kalbitor (ecallantide injection) as vials, ready to use.
Source: Kalbitor (ecallantide injection) label, sections 2, 3 and 16 (DailyMed version 19, effective July 1, 2025).
Storage before and after mixing
Before mixing or first use: “NDC (): 3 single-dose vials in 1 carton KALBITOR should be kept refrigerated (2°C to 8°C/36°F to 46°F).” “Vials removed from refrigeration should be stored below 86°F/30°C and used within 14 days or returned to refrigeration until use.”
After mixing or first use: the label sentences we read say nothing separate about this.
Source: Kalbitor (ecallantide injection) label, sections 16 and 2 (DailyMed version 19, effective July 1, 2025).
How it is taken
As the approved label gives it: Subcutaneous (Per attack; Label: acute attack of hereditary angioedema, age 12+).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of elimination half-life 2.0 ± 0.5 hours. After about five half-lives almost none is left.
How long the doses were given: Label: acute attack of hereditary angioedema, age 12+: Single dose, with one repeat allowed within 24 hours.
When effects appear: unknown; no source on this page gives a time to effect for Ecallantide. Results reported in the studies are under Published Research.
Source: half-life: Kalbitor prescribing information, section 12.3 (DailyMed set f56aec67, effective July 1, 2025); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Anaphylaxis in 3.5% of patients across 1,045 doses; No treatment-related serious adverse events in EDEMA4. Full list and cautions ↓
Boxed warning on the label: Anaphylaxis.
When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Ecallantide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: Kalbitor (ecallantide injection) label, boxed warning and section 5 (DailyMed version 19, effective July 1, 2025); the Side Effects section below (“From the studies above”).
Interactions
Unknown: a PubMed search for human interaction studies of Ecallantide (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Ecallantide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (Approved in the US as Kalbitor, BLA 125277, on December 1, 2009, for acute attacks of hereditary angioedema). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
Warnings from the Kalbitor label (DailyMed, effective July 1, 2025).
Legal Status
Ecallantide is an approved prescription biologic in the US.
Frequently Asked Questions
?Is ecallantide a peptide?
It is a 60-amino-acid protein. FDA treats chains longer than 40 amino acids as proteins, which is why ecallantide was licensed as a biologic.
?Why must a healthcare professional give it?
Because of anaphylaxis: about 3.5% of patients had anaphylactic reactions in pooled data, and the label requires administration where anaphylaxis can be treated.
?What does ecallantide treat?
Acute attacks of hereditary angioedema in people 12 and older, by blocking the enzyme that releases bradykinin.
?How is ecallantide given?
The label dose is 30 mg as three 10 mg injections under the skin during an attack; if the attack persists, another 30 mg may be given within 24 hours, always by a healthcare professional.
?How quickly does ecallantide work?
In the EDEMA4 trial, the estimated time to significant improvement was 165 minutes on ecallantide against more than 240 minutes on placebo, a difference that was not statistically significant; the main four-hour symptom score did improve significantly.
?Does ecallantide work for throat swelling?
Pooled data from four studies covered 220 laryngeal attacks in 98 patients, with a median of 185 minutes to significant improvement; one attack needed intubation.
References
- [fda] US FDA, Drugs@FDA (openFDA): KALBITOR, BLA 125277 (December 1, 2009). Read October 3, 2026.
- [fda-pi] FDA. Kalbitor (ecallantide) US prescribing information (DailyMed set f56aec67-c662-477c-b866-bfc23e8809cf, version 19, effective July 1, 2025). Read October 3, 2026.
- [clinical-trial] Cicardi M, et al. "Ecallantide for the treatment of acute attacks in hereditary angioedema." N Engl J Med, 2010;363(6):523-31. PMID: 20818887.
- [pubmed] Garnock-Jones KP. "Ecallantide: in acute hereditary angioedema." Drugs, 2010;70(11):1423-31. PMID: 20614949.
- [pubmed] Craig TJ, et al. "Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks." J Allergy Clin Immunol Pract, 2015;3(2):206-212.e4. PMID: 25609335.
- [pubmed] Duffey H, et al. "Management of acute attacks of hereditary angioedema: role of ecallantide." J Blood Med, 2015;6:115-23. PMID: 25931832.
- [clinical-trial] Lewis LM, et al. "Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial." Ann Emerg Med, 2015;65(2):204-13. PMID: 25182544.
- [pubmed] Li HH, et al. "Analysis of hereditary angioedema attacks requiring a second dose of ecallantide." Ann Allergy Asthma Immunol, 2013;110(3):168-72. PMID: 23548526.
- [pubmed] Sheffer AL, et al. "Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks." Ann Allergy Asthma Immunol, 2013;110(3):184-188.e2. PMID: 23548529.
- [pubmed] MacGinnitie AJ, et al. "Use of ecallantide in pediatric hereditary angioedema." Pediatrics, 2013;132(2):e490-7. PMID: 23878046.
- [pubmed] Bernstein JA, et al. "Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department." Ann Allergy Asthma Immunol, 2015;114(3):245-9. PMID: 25601538.
- [pubmed] Al-Adimi G, et al. "Extension of the circulatory half-life of recombinant ecallantide via albumin fusion without loss of anti-kallikrein activity." J Biotechnol, 2024;391:11-19. PMID: 38844246.
- [pubmed] Lumry WR, et al. "Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study." Allergy Asthma Proc, 2013;34(2):155-61. PMID: 23484891.
- [pubmed] Bernstein JA, et al. "Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema." Allergy, 2012;67(9):1173-80. PMID: 22765833.
- [pubmed] Bokesch PM, et al. "A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial)." J Thorac Cardiovasc Surg, 2012;143(5):1022-9. PMID: 21724197.
Sources & Citations
Studies were read from their PubMed abstracts; the Kalbitor label (DailyMed version 19, effective July 1, 2025) was read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.